Interview with our CEO, Joern Klinger, by 5-HT Startup Hub

“The development of new drugs is complex, expensive and risky. Around 90 % of clinical trials fail because of the right selection of participating patients or because the drug target turns out not to be central to the disease mechanism, after sums in the billions have already been invested.”

Our CEO, Joern Klinger, talks about biotx.ai’s ability to fix these things, our new COVID-19 treatment and other things.

Link to the interview:

https://www.5-ht.com/en/media/blog/faster-drug-development-through-genomic-data